3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
9
Phase 1
3
Phase 1/2
2
Phase EARLY_PHASE1
1
Phase 4
1
Phase 3
1
Phase 2/3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
160
Thoracic
151
Gynecologic
150
Gastrointestinal
63
Genitourinary
16
Head & Neck
14
Tumor-Agnostic
7
Dermatologic
5
Sarcoma
4
Other solid neoplasm
2
Other
1
Endocrine
1
Classical hematology
1
Conditions
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Head and Neck Neoplasms
1
Interventions
Everolimus
8
lanreotide
7
Octreotide
7
lutetium Lu 177 dotatate
6
pasireotide
5
Thyrotropin Alfa
5
Mitotane
4
Etoposide
4
Doxorubicin
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
amino-acid, glucose, and electrolyte solution
3
Mifepristone
3
Filgrastim
3
Corlux
3
Cisplatin
3
Chemotherapy, Adjuvant
3
Capecitabine
3
Cabergoline
3
vandetanib
2
telotristat ethyl
2
surufatinib
2
ribociclib
2
fluorodopa F 18
2
cabozantinib
2
Temozolomide
2
Receptor-Like Protein Tyrosine Phosphatases, Class 2
2
Lutetium-177
2
Lutetium
2
Leucovorin
2
Iodine-131
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Paclitaxel
×
Endocrine
×
Clear all
NCT01701349
2014-05-01
FACT2
Mateon Therapeutics
Phase 3
Withdrawn